Novo Nordisk A/S (NVO.N)
|Market Cap (Mil.):||$92,795.55|
|Shares Outstanding (Mil.):||2,112.56|
COPENHAGEN - Drug maker Novo Nordisk said the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion on the use of its diabetes drug Tresiba for the treatment of children and adolescents.
COPENHAGEN, Dec 19 - Drug maker Novo Nordisk said the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion on the use of its diabetes drug Tresiba for the treatment of children and adolescents.
* Has entered into a partnering contract with Novo Nordisk A/S to build a shell structure with a total gross area of 15,000 square metres
* Bay 81-8973 is based on Bayer's established Kogenate drug
OSLO, Nov 25 - The following stocks may be affected by newspaper reports and other factors on Tuesday:
COPENHAGEN, Nov 25 - Novo Nordisk A/S : ** Has reduced the number of executives from seven to six ** Executive vice president and chief of staffs Lise Kingo has decided to leave Novo Nordisk
COPENHAGEN, Nov 21 - Novo Nordisk A/S : ** Victoza receives positive Committee for Medicinal Products for Human Use opinion opinion for use in adults with type 2 diabetes and moderate renal impairment ** Once the European Commission approves the label expansion, physician s in the European Union will be able to prescribe Victoza, the once-daily human glucagon-like peptide-1 (GLP-1) analogue, to adults with type 2 diabetes and moderate renal impairment without dose adjustments
Nov 4 - Novo Nordisk A/S says: * New phase 3a data demonstrate that nine out of 10 adults with obesity lost
* Invests 750 million Danish crowns in new laboratories for diabetes research in Denmark (around $130 million)
* Shares up almost 4 percent (Adds analysts, details on Tresiba, updates shares)